Compare $LGVN vs $SKYE | Chartloom

Compare

$LGVN vs $SKYE

Longeveron Inc · Skye Bioscience Inc

LGVN

Longeveron Inc

SKYE

Skye Bioscience Inc

Compare $LGVN vs $SKYE

Comparing Longeveron Inc and Skye Bioscience Inc

LGVNLongeveron Inc

SKYESkye Bioscience Inc

LGVNLongeveron Inc

Market cap

$78M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

64.70x

Rev growth (TTM)

-42.7%

YTD performance

-58.2%

52W performance

-73.3%

FCF yield

-26.4%

SKYESkye Bioscience Inc

Market cap

$59M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-75.9%

52W performance

-87.7%

FCF yield

-65.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LGVN

SKYE

Detailed metrics comparison

LGVN

Longeveron Inc

SKYE

Skye Bioscience Inc

Market Cap

LGVN$78M

SKYE$59M

Enterprise Value

LGVN$68M

SKYE$51M

Price

LGVN$2.48

SKYE$1.69

P/E Ratio

LGVNN/A

SKYEN/A

P/S Ratio

LGVN66.02x

SKYE26.57x

EV/Sales

LGVN57.53x

SKYE0.00x

EV/EBITDA

LGVN0.00x

SKYE0.00x

P/B Ratio

LGVN0.79x

SKYE0.83x

P/FCF Ratio

LGVNN/A

SKYEN/A

EV/FCF

LGVN-3.30x

SKYE-1.31x

PEG Ratio

LGVNN/A

SKYEN/A

Forward P/E (NTM)

LGVNN/A

SKYEN/A

Forward P/S (NTM)

LGVN64.70x

SKYEN/A

Revenue (TTM)

LGVN$1M

SKYE$0

Revenue Growth (YoY)

LGVN-42.7%

SKYEN/A

Forward Rev Growth

LGVN398.7%

SKYE307.4%

Gross Margin (TTM)

LGVN69.8%

SKYE39.3%

Operating Margin (TTM)

LGVN0.0%

SKYE0.0%

EBITDA Margin (TTM)

LGVN-1907.3%

SKYE0.0%

Net Margin (TTM)

LGVN-1977.6%

SKYE0.0%

FCF Margin (TTM)

LGVN-1742.1%

SKYEN/A

Net Income (TTM)

LGVN$-23M

SKYE$-50M

FCF (TTM)

LGVN$-21M

SKYE$-39M

EPS (TTM)

LGVN-$7.48

SKYE-$10.18

ROE (TTM)

LGVN-22319.0%

SKYE-21727.0%

ROA (TTM)

LGVN-15020.0%

SKYE-20179.0%

ROIC (TTM)

LGVN-22319.0%

SKYE-21675.0%

Cash

LGVN$10M

SKYE$9M

Debt

LGVN$0

SKYE$143K

Net Cash/Debt

LGVN$10M

SKYE$8M

Current Ratio (TTM)

LGVN2.63x

SKYE0.95x

Quick Ratio (TTM)

LGVN2.35x

SKYE0.91x

Debt/Equity (TTM)

LGVN0.00x

SKYE0.03x

Debt/Assets (TTM)

LGVN0.0%

SKYE0.0%

Interest Coverage (TTM)

LGVNN/A

SKYEN/A

Net Debt/EBITDA (TTM)

LGVN0.00x

SKYE0.00x

Beta

LGVN0.85

SKYE3.13

52W Performance

LGVN-73.3%

SKYE-87.7%

YTD Performance

LGVN-58.2%

SKYE-75.9%

% from 52W High

LGVN-79.8%

SKYE-88.0%

% from 52W Low

LGVN7.8%

SKYE12.7%

Asset Turnover (TTM)

LGVN0.08x

SKYE1.93x

FCF Yield (TTM)

LGVN-26.4%

SKYE-65.4%

Earnings Yield (TTM)

LGVN-30.0%

SKYE-85.0%

Dividend Yield (TTM)

LGVNN/A

SKYEN/A

Rule of 40

LGVN-1,784.9

SKYE0.0

EV/GP/RG

LGVN40.37

SKYEN/A

Ticker research

View LGVN research View SKYE research

Metric	LGVN Longeveron Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$78M	$59M
Enterprise Value	$68M	$51M
Price	$2.48	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	66.02x	26.57x
EV/Sales	57.53x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.79x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.30x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	64.70x	N/A
Revenue & Growth
Revenue (TTM)	$1M	$0
Revenue Growth (YoY)	-42.7%	N/A
Forward Rev Growth	398.7%	307.4%
Profitability
Gross Margin (TTM)	69.8%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1907.3%	0.0%
Net Margin (TTM)	-1977.6%	0.0%
FCF Margin (TTM)	-1742.1%	N/A
Net Income (TTM)	$-23M	$-50M
FCF (TTM)	$-21M	$-39M
EPS (TTM)	-$7.48	-$10.18
ROE (TTM)	-22319.0%	-21727.0%
ROA (TTM)	-15020.0%	-20179.0%
ROIC (TTM)	-22319.0%	-21675.0%
Financial Health
Cash	$10M	$9M
Debt	$0	$143K
Net Cash/Debt	$10M	$8M
Current Ratio (TTM)	2.63x	0.95x
Quick Ratio (TTM)	2.35x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.85	3.13
52W Performance	-73.3%	-87.7%
YTD Performance	-58.2%	-75.9%
% from 52W High	-79.8%	-88.0%
% from 52W Low	7.8%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	1.93x
FCF Yield (TTM)	-26.4%	-65.4%
Earnings Yield (TTM)	-30.0%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,784.9	0.0
EV/GP/RG	40.37	N/A
Ticker research	View LGVN research	View SKYE research

Valuation

P/S Ratio

SKYE

26.57x

LGVN

66.02x

EV/FCF

LGVN

-3.30x

SKYE

-1.31x

Growth & revenue

Revenue Growth TTM

LGVN

-42.7%

Forward Revenue Growth

LGVN

398.7%

SKYE

307.4%

Profitability & performance

Gross Margin

LGVN

69.8%

SKYE

39.3%

ROE

SKYE

-21727.0%

LGVN

-22319.0%

FCF Yield %

LGVN

-26.4%

SKYE

-65.4%

52-Week Performance

LGVN

-73.3%

SKYE

-87.7%

Detailed metrics comparison

LGVN

Longeveron Inc

SKYE

Skye Bioscience Inc

Market Cap

LGVN$78M

SKYE$59M

Enterprise Value

LGVN$68M

SKYE$51M

Price

LGVN$2.48

SKYE$1.69

P/E Ratio

LGVNN/A

SKYEN/A

P/S Ratio

LGVN66.02x

SKYE26.57x

EV/Sales

LGVN57.53x

SKYE0.00x

EV/EBITDA

LGVN0.00x

SKYE0.00x

P/B Ratio

LGVN0.79x

SKYE0.83x

P/FCF Ratio

LGVNN/A

SKYEN/A

EV/FCF

LGVN-3.30x

SKYE-1.31x

PEG Ratio

LGVNN/A

SKYEN/A

Forward P/E (NTM)

LGVNN/A

SKYEN/A

Forward P/S (NTM)

LGVN64.70x

SKYEN/A

Revenue (TTM)

LGVN$1M

SKYE$0

Revenue Growth (YoY)

LGVN-42.7%

SKYEN/A

Forward Rev Growth

LGVN398.7%

SKYE307.4%

Gross Margin (TTM)

LGVN69.8%

SKYE39.3%

Operating Margin (TTM)

LGVN0.0%

SKYE0.0%

EBITDA Margin (TTM)

LGVN-1907.3%

SKYE0.0%

Net Margin (TTM)

LGVN-1977.6%

SKYE0.0%

FCF Margin (TTM)

LGVN-1742.1%

SKYEN/A

Net Income (TTM)

LGVN$-23M

SKYE$-50M

FCF (TTM)

LGVN$-21M

SKYE$-39M

EPS (TTM)

LGVN-$7.48

SKYE-$10.18

ROE (TTM)

LGVN-22319.0%

SKYE-21727.0%

ROA (TTM)

LGVN-15020.0%

SKYE-20179.0%

ROIC (TTM)

LGVN-22319.0%

SKYE-21675.0%

Cash

LGVN$10M

SKYE$9M

Debt

LGVN$0

SKYE$143K

Net Cash/Debt

LGVN$10M

SKYE$8M

Current Ratio (TTM)

LGVN2.63x

SKYE0.95x

Quick Ratio (TTM)

LGVN2.35x

SKYE0.91x

Debt/Equity (TTM)

LGVN0.00x

SKYE0.03x

Debt/Assets (TTM)

LGVN0.0%

SKYE0.0%

Interest Coverage (TTM)

LGVNN/A

SKYEN/A

Net Debt/EBITDA (TTM)

LGVN0.00x

SKYE0.00x

Beta

LGVN0.85

SKYE3.13

52W Performance

LGVN-73.3%

SKYE-87.7%

YTD Performance

LGVN-58.2%

SKYE-75.9%

% from 52W High

LGVN-79.8%

SKYE-88.0%

% from 52W Low

LGVN7.8%

SKYE12.7%

Asset Turnover (TTM)

LGVN0.08x

SKYE1.93x

FCF Yield (TTM)

LGVN-26.4%

SKYE-65.4%

Earnings Yield (TTM)

LGVN-30.0%

SKYE-85.0%

Dividend Yield (TTM)

LGVNN/A

SKYEN/A

Rule of 40

LGVN-1,784.9

SKYE0.0

EV/GP/RG

LGVN40.37

SKYEN/A

Ticker research

View LGVN research View SKYE research

Metric	LGVN Longeveron Inc	SKYE Skye Bioscience Inc
Market & Valuation
Market Cap	$78M	$59M
Enterprise Value	$68M	$51M
Price	$2.48	$1.69
P/E Ratio	N/A	N/A
P/S Ratio	66.02x	26.57x
EV/Sales	57.53x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.79x	0.83x
P/FCF Ratio	N/A	N/A
EV/FCF	-3.30x	-1.31x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	64.70x	N/A
Revenue & Growth
Revenue (TTM)	$1M	$0
Revenue Growth (YoY)	-42.7%	N/A
Forward Rev Growth	398.7%	307.4%
Profitability
Gross Margin (TTM)	69.8%	39.3%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1907.3%	0.0%
Net Margin (TTM)	-1977.6%	0.0%
FCF Margin (TTM)	-1742.1%	N/A
Net Income (TTM)	$-23M	$-50M
FCF (TTM)	$-21M	$-39M
EPS (TTM)	-$7.48	-$10.18
ROE (TTM)	-22319.0%	-21727.0%
ROA (TTM)	-15020.0%	-20179.0%
ROIC (TTM)	-22319.0%	-21675.0%
Financial Health
Cash	$10M	$9M
Debt	$0	$143K
Net Cash/Debt	$10M	$8M
Current Ratio (TTM)	2.63x	0.95x
Quick Ratio (TTM)	2.35x	0.91x
Debt/Equity (TTM)	0.00x	0.03x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.85	3.13
52W Performance	-73.3%	-87.7%
YTD Performance	-58.2%	-75.9%
% from 52W High	-79.8%	-88.0%
% from 52W Low	7.8%	12.7%
Efficiency & Yields
Asset Turnover (TTM)	0.08x	1.93x
FCF Yield (TTM)	-26.4%	-65.4%
Earnings Yield (TTM)	-30.0%	-85.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,784.9	0.0
EV/GP/RG	40.37	N/A
Ticker research	View LGVN research	View SKYE research